Recent News

• 12.12.2025 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Week Dose-Ranging Study to Assess the Efficacy and Safety of Etrasimod in Japanese Participants with Moderately to Severely Active Ulcerative Colitis
• 12.12.2025 - A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease
• 12.12.2025 - A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
• 12.12.2025 - A Phase 2a, Open-Label, Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease
• 12.12.2025 - A Phase 1/2 Substudy to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Vaccine Candidate(s) Against Infectious Respiratory Illnesses, Including COVID-19 and RSV, in Healthy Individuals
• 12.11.2025 - A Phase 3, Randomized, Double-Blind, Placebo- Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
• 12.10.2025 - A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises
• 12.09.2025 - An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
• 12.03.2025 - November Social Media Round-Up—Third-Quarter Earnings, Metsera Acquisition, and More
• 11.27.2025 - Phase 1/2 Study to Evaluate Palbociclib (Ibrance®) in Combination With Irinotecan and Temozolomide or in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent or Refractory Solid Tumors

Recent Filings

• 12.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2025 - 8-K Current report
• 11.20.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.19.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 11.18.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.13.2025 - 8-K Current report
• 11.13.2025 - 13F-HR Quarterly report filed by institutional managers, Holdings
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]